Biotie announced that its research and option agreement with Roche for the development of small molecule inhibitors of SSAO (semicarbazide-sensitive amine oxidase) has been terminated by mutual agreement. Timo Veromaa, Chief Executive Officer of Biotie commented, "We have made significant progress more
To use all functions of this page, please activate cookies in your browser.
